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Abstract 1 
At the CDKN2A/B locus, three independent signals for type 2 diabetes risk are located 2 
in a non-coding region near CDKN2A. The disease-associated alleles have been implicated in 3 
reduced β-cell function, but the underlying mechanism remains elusive. In mice, β-cell 4 
specific loss of Cdkn2a causes hyperplasia whilst overexpression leads to diabetes, 5 
highlighting CDKN2A as a candidate effector transcript. Rare CDKN2A loss-of-function 6 
mutations are a cause of familial melanoma and offer the opportunity to determine the impact 7 
of CDKN2A haploinsufficiency on glucose homeostasis in humans. To test the hypothesis 8 
that such individuals have improved β-cell function, we performed oral and intravenous 9 
glucose tolerance tests on mutation carriers and matched controls. Compared with controls, 10 
carriers displayed increased insulin secretion, impaired insulin sensitivity and reduced hepatic 11 
insulin clearance. These results are consistent with a model whereby CDKN2A-loss affects a 12 
range of different tissues, including pancreatic β-cells and liver. To test for direct effects of 13 
CDKN2A-loss on β-cell function, we performed knockdown in a human β-cell line, EndoC-14 
bH1. This revealed increased insulin secretion independent of proliferation. Overall, we 15 
demonstrate that CDKN2A is an important regulator of glucose homeostasis in humans, thus 16 
supporting its candidacy as an effector transcript for type 2 diabetes-associated alleles in the 17 
region.   18 
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Introduction 19 
Non-coding genetic signals at the CDKN2A/B locus have been associated with 20 
increased risk of developing type 2 diabetes (1, 2). One signal is contained within a long non-21 
coding RNA (ANRIL), while two distinct signals map to a region located further upstream of 22 
CDKN2A and CDKN2B. Physiological characterisations of normoglycemic carriers have 23 
demonstrated that the risk alleles are associated with reduced β-cell function, yet the 24 
underlying ‘effector’ transcript driving these effects has not been established (3, 4).  25 
CDKN2A encodes the alternatively spliced proteins p16
INK4a
 and p14
ARF
, which are 26 
known tumour suppressors acting via distinct signalling pathways (5, 6). p16
INK4a
 is a cyclin-27 
dependent kinase inhibitor (CDKI) involved in the regulation of cell cycle progression 28 
through inhibition of CDK4 and CDK6 (7). p14
ARF
, in contrast, prevents the degradation of 29 
the cell-cycle regulator p53 by forming a stable complex with Mdm2 in the nucleus (8). 30 
Rodent studies have linked Cdkn2a to glucose homeostasis, pointing to the gene as a 31 
plausible candidate effector transcript at the CDKN2A/B locus. In a β-cell specific knockout 32 
mouse, Cdkn2a deficiency was found to increase β-cell proliferation and conferred resistance 33 
to chemically-induced diabetes (9). Overexpression, in contrast, reduced β-cell proliferation 34 
in both young and old mice. This is consistent with the effect of Cdk4-loss, which has been 35 
shown to result in a reduced number of pancreatic β-cells and insulin-deficient diabetes (10). 36 
More recent mouse studies have also established a role for Cdkn2a and Cdk4 in hepatic 37 
glucose production (HGP), demonstrating cell-cycle independent effects on gluconeogenesis 38 
under fasted and fed conditions (11, 12).  39 
While rodent studies have provided critical clues into the contribution of Cdkn2a to 40 
diabetes pathogenesis, less is known about the role of CDKN2A in glucose homeostasis in 41 
humans. The machinery regulating the G1/S transition in adult human β cells differs from 42 
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that of mouse β cells, which do not express CDK6 (13-15). Individuals heterozygous for 43 
germline loss-of-function mutations in the CDKN2A gene have a high risk of developing 44 
(multiple) cutaneous melanoma, a condition known as familial atypical multiple mole 45 
melanoma syndrome (FAMMM) (16, 17). These subjects provide a unique opportunity to 46 
study the effect of CDKN2A haploinsufficiency on glucose homeostasis in humans. The 47 
present study tested the hypothesis that mutation carriers show improved β-cell function 48 
compared with non-carriers.   49 
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Research design and methods  50 
Study participants 51 
Thirty-one cases diagnosed with FAMMM due to CDKN2A mutations were recruited 52 
from centres in the UK and the Netherlands. Twenty-eight had been cancer free for at least 53 
two years, and the remaining three cases had presented with melanoma between four to 54 
twelve months prior to inclusion in the study (supplementary table 1). For a control group 55 
of thirty-one participants, unaffected first-degree relatives or spouses of carriers were chosen 56 
when available and additional controls were recruited from the Oxford Biobank 57 
(www.oxfordbiobank.org.uk). Two controls were subsequently excluded based on 2-h OGTT 58 
glucose levels diagnosing diabetes (serum glucose >11 mmol/L). All remaining participants 59 
were aged 18-80 years, not suffering from diabetes, and not taking any medication that could 60 
interfere with glucose tolerance.  61 
Baseline clinical characteristics and oral glucose tolerance test (OGTT) 62 
 All participants underwent a 75 g OGTT following a 12 hour fast.  Blood samples 63 
were collected at 0, 15, 30, 60, 90 and 120 min after the oral glucose load to assay plasma 64 
glucose, serum insulin and (for a subset of twelve mutation carriers and twelve controls) also 65 
C-peptide. Insulin and C-peptide were measured using chemiluminescence immunoassays. 66 
Measures of insulin sensitivity, β-cell function and hepatic clearance derived from the OGTT 67 
were calculated according to the formulae in supplementary table 2.  68 
Intravenous glucose tolerance test (IVGTT) 69 
IVGTTs were performed on a subset of the UK subjects (eight) who had attended for 70 
OGTT and consented to undergo an IVGTT. Control subjects, matched for age, gender, BMI 71 
and activity were recruited from the Oxford Biobank. Following a 12 hour fast, a dose of 50 72 
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% dextrose (calculated based on weight 0.5mg/kg) was given over 3 minutes. Blood samples 73 
were then taken at 0, 2, 4, 6, 8, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150 and 180 minutes.  74 
These samples were batch-analysed for insulin, glucose and C-peptide. Data were then 75 
analysed using a minimal model approach, according to an algorithm designed to maximise 76 
precision and identification success rate (18).  77 
Cellular assays using the EndoC-bH1cell line 78 
The EndoC-bH1 cell line was cultured and passaged as previously described (19). 79 
Reverse transfections were performed by adding pre-formed siRNA complexes prepared 80 
from ON-TARGETplus siRNA SMARTpools (Dharmacon) at a final concentration of 10 nM 81 
siRNA. For gene expression analysis, RNA was extracted and quantitative PCR (qPCR) 82 
performed using the TaqMan gene expression kit and assays (Applied Biosystems) on oligo-83 
dT primed cDNA. 72 h after transfection, cells were starved overnight in 2.8 mM glucose 84 
followed by 1 h in 0 mM glucose medium. Static insulin secretion assays were then initiated 85 
by adding glucose-free growth medium supplemented with the indicated amounts of glucose 86 
and IBMX. After 1 h, aliquots of supernatants were removed for later analysis, and ice-cold 87 
acid ethanol added to extract insulin content from cells. Sample analysis was performed using 88 
the AlphaLISA Human Insulin Immunoassay (Perkin Elmer). 89 
For protein kinase A (PKA) activity assays, cells were harvested following knockdown, as 90 
described above, and washed in phosphate-buffered saline. Matching input for number of 91 
cells, the samples were then processed according to manufacturer’s instructions for the 92 
PepTag non-radioactive PKA assay (Promega), and visualized using the ChemiDoc MP 93 
system.   94 
Statistical analysis 95 
Page 7 of 36 Diabetes
7 
 
Statistical analysis was performed using R 3.0.2. P-values were determined by Welch’s t-test, 96 
except for gender differences where the Chi-squared test was used and for analysis of the 97 
IVGTT data where the Mann-Whitney U test was used. 98 
99 
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Results 100 
We recruited thirty-one participants carrying inherited CDKN2A loss-of-function 101 
mutations (supplementary table 1) and thirty-one controls, matched as a group for age (p = 102 
0.99), gender (p = 0.43) and BMI (p = 0.97) (table 1). To test our hypothesis that CDKN2A-103 
loss leads to improved β-cell function, we first performed a 120-min oral glucose tolerance 104 
test (OGTT) in all subjects (figure 1a-b). While no difference in glucose levels was detected, 105 
insulin levels were significantly increased in carriers throughout the test (p = 0.01 for insulin 106 
area under curve [AUC]; table 2).  107 
Using these data, we derived standard indices of β-cell function and insulin sensitivity 108 
(table 2). This revealed increased β-cell function in carriers compared with non-carriers, both 109 
using a dynamic measure of acute insulin response (p = 0.03 for BIGTT-AIR), and in the 110 
fasted state (p = 0.05 for HOMA-B, homeostatic model assessment of β-cell function). 111 
Corresponding measures of insulin sensitivity, BIGTT-S and HOMA-S (homeostatic model 112 
assessment of insulin sensitivity), were also both found to be lower in carriers (p = 0.04 and p 113 
= 0.05, respectively). Other standard measures, the Belfiore and Matsuda ISIs, confirmed the 114 
observed reduction in insulin sensitivity of carriers (p = 0.02 and p = 0.02, respectively). As a 115 
result, the disposition index, which is an aggregate measure of β-cell function relative to 116 
glucose sensitivity, remained unaffected compared with controls (p = 0.98). These results 117 
were not significantly altered by exclusion of three carriers that had presented with melanoma 118 
within two years prior to inclusion in the study (supplementary table 3). 119 
To explore whether the observed phenotype was driven by underlying effects on 120 
p16
INK4a
, p14
ARF
 or both, we re-analysed the data grouping carriers by mutation status 121 
(supplementary figure 1). Of the mutations identified, 26 affected both p16
INK4a
 and p14
ARF
, 122 
while five were located in regions affecting p16
INK4a
 exclusively. No differences were 123 
observed between these two groups in insulin or glucose levels (p = 1.00 for AUCins and p = 124 
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0.49 for AUCglucose, respectively), suggesting that the observed metabolic phenotype of 125 
mutation carriers may be driven either solely by effects on p16
INK4a
, or by effects of similar 126 
magnitude on both proteins.  127 
For a subset of participants (twelve carriers and twelve controls) C-peptide 128 
measurements were obtained during the OGTT. Despite a tendency towards increased C-129 
peptide levels in the fasted state (p = 0.48), the total response was not different for this subset 130 
of individuals (p = 1.00 for AUC). Indices of hepatic insulin clearance, derived from the ratio 131 
between C-peptide and insulin levels, however, showed significantly decreased hepatic 132 
clearance in mutation carriers (p = 0.03; table 2) (20).  133 
To confirm these findings, we performed IVGTTs on eight cases and eight controls 134 
available for follow-up studies (supplementary figure 2). None of the measures derived 135 
from this test reached statistical significance, but directions of effect were confirmed for both 136 
insulin secretion (p = 0.14 for AUCinsulin 10-180 min) and hepatic insulin clearance (p = 0.21) 137 
(supplementary table 4). The insulin response was found to be 66 % and 110 % higher for 138 
carriers during the first and second phase of secretion, respectively. In contrast, the C-peptide 139 
response (which is unaffected by hepatic clearance) was around 30 % higher during both 140 
phases of secretion, indicating a direct contribution of improved β-cell function to the 141 
elevated circulating insulin levels of carriers.  142 
Finally, we sought to establish the extent to which cell-cycle independent effects of 143 
CDKN2A on the regulation of insulin secretion could contribute to the phenotype of mutation 144 
carriers. Recent work in rodent hepatocyte models has suggested a role of CDKN2A in the 145 
regulation of protein kinase A (PKA) signalling (12). Given the well-characterised effects of 146 
PKA on potentiation of insulin secretion, we speculated that such signalling events could 147 
have a direct effect on β-cell function. To test this hypothesis, we performed knockdown and 148 
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secretion studies in the human pancreatic β-cell line, EndoC-bH1. This cell line was 149 
transformed by Ravassard et al using the proto-oncogene SV40LT, which acts on the 150 
Retinoblastoma protein (Rb), thereby masking effects of p16
INK4a
 on cell-cycle control (19).  151 
We first confirmed expression of p16
INK4a
 by immunofluorescence and found that, 152 
consistent with previous reports, the protein localized to both the nucleus and cytoplasm 153 
(supplementary figure 3) (21, 22). siRNA-mediated silencing of CDKN2A was then 154 
performed and efficient knockdown observed both at the mRNA and protein level (figure 2a-155 
b; supplementary figure 4). 96 hours after gene silencing, cells treated with CDKN2A or 156 
non-targeting siRNAs were incubated under different conditions to assess the glucose-157 
responsiveness of the cells. In addition to basal and high-glucose conditions, the effect of the 158 
phosphodiesterase inhibitor (IBMX) on insulin secretion was tested. For all three conditions, 159 
CDKN2A knockdown was found to increase insulin secretion as a fraction of total content 160 
(basal, p = 0.02; high, p = 0.01; high glucose with IBMX, p = 0.04; figure 2c-d) and, as 161 
expected, no effect on proliferation was detected. We also observed a small, but significant 162 
reduction in the total insulin content per cell (p < 0.01; supplementary figure 5). Finally, we 163 
performed PKA activity assays to directly assess the effect of CDKN2A silencing on the 164 
potentiating pathway of insulin secretion. Consistent with an increase in insulin secretion, this 165 
revealed a corresponding 23 % increase in the activity of PKA following CDKN2A 166 
knockdown (p = 0.02; supplementary figure 6). 167 
Discussion 168 
Individuals carrying heterozygous loss-of-function mutations in the CDKN2A gene 169 
provide a unique opportunity to study the role of p16
INK4a
 and p14
ARF
 in glucose homeostasis 170 
in humans. Through oral and intravenous glucose tolerance tests, we found that carriers 171 
displayed significantly increased insulin levels compared with matched controls. In a subset 172 
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of individuals, measurements of C-peptide levels established a contribution of both decreased 173 
hepatic insulin clearance and increased β-cell function to the elevated circulating insulin. 174 
Further, grouping carriers by mutation status showed the effects to be driven either by 175 
p16
INK4a
 exclusively or through similar effects on both p16
INK4a
 and p14
ARF
.  176 
Overall, these results are consistent with a combination of two, non-mutually 177 
exclusive mechanisms underlying the phenotype of carriers: (a) primary β-cell hyperfunction 178 
driving progressive insulin resistance; and/or (b) primary insulin resistance triggering a 179 
compensatory increase in insulin levels (supplementary figure 7). While both explanations 180 
are consistent with our data, existing evidence strongly support a role for CDKN2A in β-cell 181 
function (9). Chronic hyperinsulinemia is known to result in a gradual down-regulation of 182 
both insulin receptors and post-receptor signalling efficiency, thereby causing general insulin 183 
resistance and reduced insulin clearance (23). Our data are therefore in agreement with the 184 
expected physiological adaption to chronic hyperinsulinemia. However, due to limitations on 185 
the design of our clinical study, we cannot conclusively address the cause and effect between 186 
hyperinsulinemia and insulin resistance in mutation carriers. The IVGTT is well validated 187 
against clamp-based techniques, but power calculations based on our results suggest that an 188 
impractically high number of 50-60 individuals would be required to establish significant 189 
differences. Given the rarity of the disease, this exceeds the number of carriers available in 190 
the UK and Dutch cohorts recruited for our study.  191 
To test for a cell-cycle independent role of CDKN2A in the regulation of insulin 192 
secretion, we performed knockdown studies in the human β-cell line, EndoC-bH1. This 193 
identified cell-cycle independent increases in insulin secretion under three conditions. These 194 
changes were found to be accompanied by increased PKA activity, in agreement with 195 
previous studies establishing such an effect of CDKN2A knockdown in liver (11, 12). This 196 
suggests a possible contribution of the PKA-dependent potentiating pathway to the secretory 197 
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effects observed in the EndoC-bH1 cell line. Taken in combination with existing data, our 198 
clinical and cellular studies indicate that the phenotype of carriers may arise out of a complex 199 
interplay between both cell-cycle independent and dependent roles of CDKN2A in a range of 200 
tissues (supplementary figure 7) (9, 12). 201 
Upstream of the CDKN2A and CDKN2B genes, several independent association 202 
signals for type 2 diabetes risk have been identified. The underlying effector transcript and 203 
disease mechanism has remained elusive, and prior studies have not reported any cis-204 
expression quantitative trait loci (cis-eQTL) effects for these alleles (24). Our study has 205 
shown that both coding CDKN2A mutations and the non-coding type 2 diabetes variants are 206 
associated with effects on measures of β-cell function. This provides a link between 207 
CDKN2A and the common GWAS alleles, and thus points to the gene as a likely effector 208 
transcript at this locus.  209 
Interestingly, type 2 diabetes-associated variants at the CDKN2A/B locus have 210 
consistently been linked to a more ‘classic’ β-cell phenotype than that observed for carriers of 211 
coding mutations in our study, with no evidence for an impact on measures of insulin 212 
resistance (3, 4). We speculated that any cis-regulatory effect exerted on CDKN2A could 213 
achieve a more restricted β-cell phenotype through tissue-specific regulation of gene 214 
expression. To address this hypothesis, we interrogated existing genome annotations, and 215 
found that the non-coding disease-associated variants map to a cluster of islet enhancer 216 
activity and open chromatin. Specifically, the association signals overlap a strong enrichment 217 
for islet- and melanocyte-specific FOXA-2 binding (supplementary figure 8) (25). This 218 
highlights a possible mechanism for the more specific β-cell phenotype caused by common 219 
disease-associated variants compared with carriers of coding variants. Based on the direction 220 
of effect on measures of β-cell function, the non-coding risk alleles would be predicted to 221 
increase expression of CDKN2A (3, 4). No cis-eQTL effects have previously been reported in 222 
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islets for this region, but larger studies currently underway may be able to shed further light 223 
on this hypothesis (26). 224 
Taken together, our data establish CDKN2A as an important regulator of glucose 225 
homeostasis in humans. We have shown that our data are consistent with loss-of-function 226 
mutations in CDKN2A affecting a range of tissues, including both pancreatic β-cells and 227 
liver. Our study thus supports the candidacy of CDKN2A as the effector transcript of the type 228 
2 diabetes-associated alleles in the region, and we have proposed a mechanism to account for 229 
the apparent tissue-specificity of the β-cell dysfunction caused by diabetes risk alleles. 230 
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Table 1 Baseline characteristics of study participants. Data are given as mean and range 
[min; max]. P-values are from Welch's t-test except for gender distribution where the Chi-
squared test was performed. 
 
  
 Mutation carriers  Non-carriers  P-value 
n 31  31  NA 
BMI / [cm/kg
2
] 27.1 [19; 38]  27.1 [19; 36]  0.97 
Age / [yrs] 51.8 [21; 71]  51.8 [25; 84]  0.99 
Gender / [% male] 45  32  0.43 
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Mutation carriers Non-carriers P-value 
Fasting glucose [mmol/L] 5.2 [4.3; 6.3] 
 
5.1 [3.2; 6.4] 
 
0.65 
Fasting insulin [pmol/L] 87 [15; 337] 
 
55 [22; 150] 
 
0.01 
Fasting C-peptide [nmol/L]  0.44 [0.24; 0.81]  0.39 [0.20; 0.60]  0.48 
iHOMA-B 124 [38.1; 452.4]  96 [45; 236.7]  0.05 
iHOMA-S 91 [18; 328.7]  120 [35; 235.6]  0.05 
BIGTT-AIR [*10
3
] 6.4 [0.9; 28]  3.0 [1.2; 12]  0.03 
BIGTT-S 5.8 [0.4;  12.8]  7.8 [1.1; 17.8]  0.04 
Belfiore ISI 0.78 [0.17; 1.35]  0.97 [0.35; 1.77]  0.02 
Matsuda ISI 4.3 [0.8; 11.1]  6.3 [1.5; 20.9]  0.02 
AUCglucose  839 [563; 1449]  829 [502; 1086]  0.79 
AUCinsulin [*10
4
] 7.3 [2.4; 25]  4.7 [1.1; 15]  0.01 
AUCC-Peptide   212 [106; 333]  212 [115; 260]  1.00 
Insulinogenic index 203 [39; 561]  152 [53; 360]  0.08 
C-peptidogenic index   0.45 [0.15; 1.12]  0.45 [0.17; 1.78]  1.00 
Disposition index 2.3 [1.1; 3.8]  2.3 [1.0; 3.7]  0.98 
Fasting insulin clearance  0.66 [0.12; 1.27]  0.88 [0.65; 1.29]  0.07 
Insulin clearance  0.35 [0.16; 0.51]   0.56 [0.32; 1.05]   0.03 
 
Table 2 OGTT-derived measures of β-cell function, insulin sensitivity and hepatic clearance. 
Data are given as mean and range [min; max]. All indices based on C-peptide measurements 
are based on data from a subset of individuals only (n = 12 carriers and n = 12 controls; all 
UK). Details on definitions of physiological measures are listed in supplementary table 2.  
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Figure legends 
Figure 1 Serum glucose (left panel) and insulin (right panel) levels during a 120-min OGTT 
in thirty-one carriers (black squares, solid line) and thirty-one controls (white circles, dashed 
line). Data shown as mean +/- SEM. 
Figure 2 CDKN2A knockdown in the human β-cell line, EndoC-bH1. Silencing of CDKN2A 
(white bars) and non-targeting sequence (black bars) was performed using pools of siRNA 
(10 nM), and knockdown confirmed both at the mRNA level (upper left panel) and at the 
protein level (upper right panel) after 72 h. Static insulin secretion assays were performed 
under culturing conditions of basal glucose (2.8 mM glucose), high glucose (20 mM) and 
high glucose with IBMX (100 µM) (lower left panel). All secretion results were normalized 
to total insulin content per well. Cellular proliferation (lower right panel) following treatment 
with si-CDKN2A (white circles, dashed line) and non-targeting siRNA (black squares, solid 
line) was measured using the CyQUANT Direct Cell Proliferation assay, and normalized to 
the respective counts on day 1. Bars represent means for n = 11 (si-CDKN2A) and 18 (non-
targeting) generated in three independent experiments. Data points for cellular proliferation 
are means for n = 3, and error bars are SEM. 
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Participant 
ID 
Transcript affected Mutation Melanoma-free 
for > 2 years 
prior to study 
Variant Effect 
Predictor (VEP - 
Ensembl) 
OX_001 P16-INK4a only c.88delG Yes Frameshift variant 
OX_002 P16-INK4a only c.88delG Yes Frameshift variant 
OX_003 P16-INK4a only c.88delG Yes Frameshift variant 
OX_004 Both c.458-105A>G Yes Intronic variant 
OX_005 Both c.458-105A>G Yes Intronic variant 
OX_006 Both c.458-105A>G Yes Intronic variant 
OX_007 P16-INK4a only c.52_57dup Yes Protein altering variant 
OX_008 P16-INK4a only c.52_57dup Yes Protein altering variant 
OX_009 Both c.159G>A Yes Missense variant 
OX_010 Both c.159G>A Yes Missense variant 
OX_011 Both c.458-105A>G Yes Intronic variant 
OX_012 Both Not tested Yes NA 
LEI_001 Both c.225_243del19 No Frameshift variant 
LEI_002 Both c.225_243del19 Yes Frameshift variant 
LEI_003 Both c.225_243del19 Yes Frameshift variant 
LEI_004 Both c.225_243del19 Yes Frameshift variant 
LEI_005 Both c.225_243del19 Yes Frameshift variant 
LEI_006 Both c.225_243del19 Yes Frameshift variant 
LEI_007 Both c.225_243del19 Yes Frameshift variant 
LEI_008 Both c.225_243del19 Yes Frameshift variant 
LEI_009 Both c.225_243del19 Yes Frameshift variant 
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LEI_010 Both c.225_243del19 Yes Frameshift variant 
LEI_011 Both c.67G>C No Missense variant 
LEI_012 Both c.225_243del19 No Frameshift variant 
LEI_013 Both c.225_243del19 Yes Frameshift variant 
LEI_014 Both c.225_243del19 Yes Frameshift variant 
LEI_015 Both c.225_243del19 Yes Frameshift variant 
LEI_016 Both c.225_243del19 Yes Frameshift variant 
LEI_017 Both c.225_243del19 Yes Frameshift variant 
LEI_018 Both c.225_243del19 Yes Frameshift variant 
LEI_019 Both c.225_243del19 Yes Frameshift variant 
 
Supplementary table 1 List of mutations identified in carriers (annotated against CDKN2A-
001 [ENST00000304494]) by targeted sequencing. The second column indicates whether the 
mutation maps to a region encoding just p16INK4a or both p16INK4a and p14ARF. Participant ID 
is an anonymous number assigned to each case, and the prefix indicates from which cohort 
the patient was recruited (OX = Oxford, UK; LEI = Leiden, Netherlands).  
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 Supplementary table 2 Definitions of physiological measurements and indices derived from the OGTT. Subscripts denote time points during 
the OGTT. Units are pmol/L for insulin, nmol/L for C-peptide and mmol/L for glucose, except in the case of Matsuda ISI and the disposition 
index, where glucose was inputted in units of mg/dL and insulin as µU/mL. 
Measure/index Parameter Formula or mathematical model used Reference 
iHOMA-B Beta-cell function Computer model available via (http://www.dtu.ox.ac.uk/homacalculator/). (1) 
iHOMA-S Insulin sensitivity Computer model available via (http://www.dtu.ox.ac.uk/homacalculator/). (1) 
BIGTT-AIR0-30-120   Beta-cell function exp[8.20 + (0.00178 * insulin0) + (0.00168 * insulin30) -(0.000383 * insulin120) 
- (0.314 * glucose0) - (0.109 * glucose30) + (0.0781 * glucose120) + (0.180 * 
gender (where male=0 and female=1)) - (0.032 * BMI)] 
(2) 
BIGTT-SI_0-30-120 Insulin sensitivity exp[4.90 - (0.00402 * insulin0) - (0.000556 * insulin30) -(0.00127 * insulin120) - 
(0.152 * glucose0) - (0.00871 * glucose30) - (0.0373 * glucose120) - (0.145 * 
gender (where male=0 and female=1)) - (0.0376 * BMI)] 
(2) 
Belfiore ISI Insulin sensitivity 2/[(0.5 * glucose0 + glucose60 + 0.5 * glucose120)/11.36) *  
(0.5* insulin0 + insulin60 + 0.5* insulin120)/638) + 1] 
(3) 
Matsuda ISI Insulin Sensitivity 10 000 * √(glucose0* insulin0 * glucosemean-OGTT * insulinmean-OGTT) (4) 
AUC Multiple Area under curve estimated using trapezoidal rule (5) 
Insulinogenic index
 
Beta-cell function (insulin30 – insulin0)/(glucose30 - glucose0) (6) 
Disposition index Beta-cell function AUCinsulin-OGTT/AUCglucose-OGTT  * Matsuda ISI (6) 
Hepatic insulin clearance Insulin clearance AUCC-Peptide/AUCInsulin (7) 
Fasting insulin clearance Insulin clearance C-peptide0/insulin0 (7) 
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Mutation carriers Non-carriers P-value 
n 28 31 NA 
BMI [cm/kg2] 27 [19, 38] 27 [19, 37] 0.66 
Age [yrs] 51 [21, 71] 52 [25, 84] 0.96 
Gender [% male] 43 33 0.58 
Fasting glucose [mmol/L] 5.1 [4.3, 6.3] 
 
5.1 [3.2, 6.4] 
 
0.92 
Fasting insulin [pmol/L] 91 [15, 337] 
 
57 [22, 150] 
 
0.01 
iHOMA-B 133 [38, 452] 
 
99 [45, 237] 
 
0.03 
iHOMA-S 86 [18, 329]  116 [35, 236]  0.04 
BIGTT-AIR [*103] 6.6 [0.9, 28]  3.2 [1.2, 12]  0.03 
BIGTT-S 5.8 [0.4,  12.7] 
 
7.5 [1.1, 17.8] 
 
0.08 
Belfiore ISI 0.80 [0.17, 1.35]   0.96 [0.35, 1.77]   0.03 
Matsuda ISI 4.3 [0.8; 11.1]  6.1 [1.5; 20.9]  0.02 
AUCglucose 831 [563, 1449]  832 [502, 1086]  0.98 
AUCInsulin [*104] 7.2 [2.4, 25]  4.9 [1.1, 15]  0.02 
Insulinogenic index 205 [39, 561] 
 
155 [53, 360] 
 
0.10 
Disposition index 2.3 [1.1, 3.8] 
 
2.3 [1.0, 3.7] 
 
0.92 
 
Supplementary table 3 Comparison of OGTT-derived measures for carriers and non-carriers 
after exclusion of three subjects that had presented with cancer within two years prior to the 
study (supplementary table 1). Data are given as mean and range [min; max], and p-values 
are from Welch's t-test, except for gender distribution where the Chi-squared test was 
performed. Details on definitions of physiological measures are listed in supplementary table 
2. * P-value < 0.05.  
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 Mutation carriers  Non-carriers  P value 
n 8  8  NA 
AUCinsulin 0-10 min (pmol.L-1.min*10-3) 4.8 [1.73, 13.2]  2.9 [1.84, 4.28]  0.51 
AUCinsulin 10-180 min (pmol.L-1.min*10-3) 35.5 [13.7, 94.9]  16.9 [12.5, 22.2]  0.16 
AUCC-peptide 0-10 min (pmol.L-1.min*10-3) 15.1 [9.1, 31.9]  11.7 [5.5, 14.5]  0.96 
AUCC-peptide 10-180 min (pmol.L-1.min*10-3) 198 [103, 364]  152 [101, 186]  1.00 
Net IVGTT insulin secretion 0-10 min (pmol.L-1) 0.56 [0.29, 0.84]  0.50 [0.10, 1.04]  0.65 
Net IVGTT insulin secretion 10-180 min (pmol.L-1) 4.2 [1.20, 11.8]  2.8 [1.10, 4.98]  0.65 
Insulin sensitivity, SI (min-1.pmol-1.L) 0.72 [0.19, 1.28]  0.68 [0.30, 0.95]  0.72 
Disposition index [*10-3] 2.4 [1.14, 4.44]  1.9 [0.77, 3.40]  0.51 
C-peptide disposition index 8.9 [3.45, 12.6]  7.8 [4.00, 13.7]  0.80 
Fractional hepatic insulin throughput 0.53 [0.34, 1.12]  0.41 [0.26, 0.74]  0.23 
Plasma insulin elimination rate (min-1) 0.098 [0.025, 0.207]  0.095 [0.042, 0.235]  0.72 
 
Supplementary table 4 IVGTT-derived measures of β-cell function, insulin sensitivity and hepatic clearance. Data are given as mean and range 
[min; max]. All p-values are based on Mann-Whitney U test.  
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Supplementary figure legends 
Supplementary figure 1 Serum glucose (left panel) and insulin (right panel) levels during a 
120-min OGTT in twenty-six cases with CDKN2A loss-of-function mutations affecting both 
p16INK4a and p14ARF (black triangles, dotted line), five cases with CDKN2A loss-of-function 
mutations affecting p16INK4a exclusively (black squares, solid line), and thirty-one BMI-, age-
, and gender-matched controls (white circles, dashed line). Data shown as mean +/- SEM. 
Supplementary figure 2 Serum glucose (left panel) and insulin (right panel) levels during a 
180-min IVGTT in eight carriers (pink circles) and eight BMI- (p = 0.72), age- (p = 0.96), 
and gender-matched (p = 0.50) controls (blue squares). Data shown as mean +/- SEM. 
Supplementary figure 3 Immunofluorescence staining of p16INK4a (Abcam, ab81278; 
recognizing isoform 1 of the protein) in the human beta-cell line, EndoC-bH1. In siRNA-
mediated knockdown experiments, expression of p16INK4a protein was visibly down-
regulated (bottom panel) as compared with control cells (top panel). Cell nuclei were stained 
using NucRed Dead 647 (Life Technologies). Images were taken on a BioRad Radiance 2100 
confocal microscope with a 60X 1.0 N.A. objective, and the same laser settings and 
intensities were used across samples. Scale bar, 20 µm. 
Supplementary figure 4 Gene expression profiles of critical cell-cycle regulators after 
silencing of CDKN2A in the human β-cell line, EndoC-bH1. Knockdown experiments were 
performed as described for figure 2. Relative gene expression of CDK4 (top left), CDK6 (top 
right), CDKN2A (bottom left) and CDKN2B (bottom right) corrected for expression of two 
housekeepers using the delta-delta Ct method, and normalized to non-targeting control. As 
shown, we observed efficient knockdown of CDKN2A with no off-target effect on the 
CDKN2B gene. Bars represent means for n = 4-5 and error bars are SEM. 
Supplementary figure 5 Insulin content normalized to cell-count following CDKN2A 
knockdown. After static insulin secretion assays, cells were counted and insulin contents 
extracted as described in figure 2. Using these data, the insulin content relative to the number 
of cells per well was calculated as the ratio between these two numbers, and normalized to 
scrambled control. Bars represent means for the aggregate of basal and high glucose 
measurements for n = 16, and error bars are SEM. 
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Supplementary figure 6 PKA activity in the EndoC-bH1 cell line following CDKN2A 
knockdown. 96 h after treatment with non-targeting (“scrambled”; blue bar) or CDKN2A (red 
bar) siRNAs, cells were harvested and PKA activity measured on sample input normalized to 
cell numbers. Substrate conversion rates were calculated as the ratio of non-phosphorylated 
to total peptide using fluorescence intensities quantified with standard software on the 
ChemiDoc MP system. Data shown as mean +/- SEM for three independent replicates.  
Supplementary figure 7 Outline of two non-mutually exclusive mechanisms compatible 
with the phenotype of CDKN2A mutations-carriers. According to model 1 (left), a primary 
reduction in insulin sensitivity leads to a compensatory increase in insulin secretion to 
maintain glucose homeostasis. The effect of CDKN2A-loss would therefore be in non-beta 
cell tissues, such as liver. Model 2 (right), in contrast, represent the alternative scenario: 
chronically elevated insulin levels due to β-cell hypersecretion drives a progressive decrease 
in insulin receptors and insulin signalling through homologous desensitization (8). In this 
case, the primary effect of CDKN2A loss is on the pancreatic beta-cell, but the mechanism 
ultimately manifests as impaired insulin sensitivity and reduced insulin clearance. As 
discussed in the main text, it is likely that a combination of the two models contributes to 
both beta-cell hypersecretion and primary insulin resistance.  
Supplementary figure 8 Screenshot from the Human Islet Regulome Browser (9) showing 
annotations of chromatin state, transcription factor binding and variant association with type 
2 diabetes at the CDKN2A/B locus. The genomic binding sites of islet transcription factors 
(PDX1, NKX2.2, FOXA2, NKX6.1, MAFB) are indicated by lines connected to the 
respective proteins. A Manhattan plot above shows log(p-values) of association with type 2 
diabetes for variants in the MAGIC (blue) and DIAGRAM (red) datasets (10, 11). Lead 
variants tagging the two genome-wide association signals located downstream of CDKN2B-
AS1 are shown. Fine-mapping efforts have since publication of the islet regulome narrowed 
down the number of potential causative variants to credible sets of five and six variants 
(Gaulton et al, (2015) Nature Genetics, in press). Both of these sets contain variants that 
directly overlap a FOXA2 binding site. 
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